AI-generated analysis. Always verify with the original filing.
DBV Technologies S.A. reported full year 2025 financial results including operating income of $5.6 million, net loss of $147.0 million, and cash and cash equivalents of $194.2 million as of December 31, 2025, plus $94 million additional proceeds received January 16, 2026, funding into Q2 2027. The company advanced VIASKIN Peanut Patch clinical programs, bolstered leadership, and anticipates BLA submissions in 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exch
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated March 26, 2026. 104 Cover Page Interactive Data File (embedded with
| Metric | Value | Basis |
|---|---|---|
| Operating Income | $5.60 | |
| Research and Development Expenses | $116.70 | |
| Sales and Marketing Expenses | $3.20 | |
| General and Administrative Expenses | $32.80 | |
| Net Loss | $147.00 | |
| Net Loss per Share | $1.05 |
Kevin Trapp
James Briggs
Philina Lee, Ph.D.